News
ENTA
8.40
-3.34%
-0.29
Enanta Pharmaceuticals Becomes Oversold (ENTA)
NASDAQ · 17h ago
H.C. Wainwright sees ‘incremental disappointment’ in Enanta Q4 report
TipRanks · 22h ago
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Moleculin Biotech (MBRX)
TipRanks · 22h ago
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026
NASDAQ · 1d ago
Closing Bell Movers: Aecom up over 6% after Q4 beat
TipRanks · 1d ago
Enanta Logs Wider 4Q Loss, Lower Revenue on Declining Hepatitis C Treatment Royalties
Dow Jones · 1d ago
Enanta Pharma Q4 EPS $(0.81) Misses $(0.78) Estimate, Sales $12.868M Miss $14.200M Estimate
Benzinga · 1d ago
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 1d ago
Enanta reports Q4 EPS (81c), consensus (77c)
TipRanks · 1d ago
Enanta Pharma GAAP EPS of -$0.81 misses by $0.04, revenue of $12.87M misses by $2.85M
Seeking Alpha · 1d ago
*Enanta Pharmaceuticals 4Q Loss/Shr 81c >ENTA
Dow Jones · 1d ago
Press Release: Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026
Dow Jones · 1d ago
Press Release: Enanta Pharmaceuticals Reports -3-
Dow Jones · 1d ago
Press Release: Enanta Pharmaceuticals Reports -2-
Dow Jones · 1d ago
*Enanta Pharmaceuticals 4Q Rev $12.9M >ENTA
Dow Jones · 1d ago
*Enanta Pharmaceuticals 4Q Loss $23.7M >ENTA
Dow Jones · 1d ago
Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot
Barchart · 2d ago
Weekly Report: what happened at ENTA last week (1109-1113)?
Weekly Report · 2d ago
BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 6d ago
Immatics (IMTX) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 11/10 12:15
More
Webull provides a variety of real-time ENTA stock news. You can receive the latest news about Enanta Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENTA
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.